Lucid Diagnostics advanced payment, billing and coding pathways for EsoGuard and EsoCheck, including a proposed ICD-10-CM code, R85.83, for positive test results. The developments matter because they could support Medicare claims, physician reporting of EsoCheck procedures and documentation for confirmatory endoscopy once the relevant decisions and codes take effect.
Key Highlights
- An AMA panel approved a new Category III CPT code for nonendoscopic esophageal cell collection performed with EsoCheck.
- A proposed ICD-10-CM code, R85.83, received a positive response for reporting positive EsoGuard results tied to confirmatory upper endoscopy.
- The recommendation applies to PLA code 0114U.
- CMS is expected to make final determinations in November after public comment.
Medicare Payment and New Reporting Codes
The developments cover Medicare payment, physician reporting and diagnosis coding. The recommendation applies to PLA code 0114U, and a consent agenda reflecting it has been posted. The Centers for Medicare & Medicaid Services is expected to make final determinations in November after a public comment period. The AMA is expected to publish its meeting summary in the coming weeks.
Claims and Diagnosis Coding Pathways
The proposal received a positive response and is expected to proceed through a public comment process. The proposed code would support claims for subsequent confirmatory upper endoscopy by giving physicians a dedicated way to document the clinical rationale. Lucid (NASDAQ: LUCD) plans to begin submitting Medicare claims under PLA code 0114U for testing at its Texas laboratory this month.
FAQs
Q: What Medicare payment decision affects Lucid Diagnostics’ EsoGuard test?
A: The article does not state the Medicare payment decision itself. It states that the recommendation applies to PLA code 0114U and that CMS is expected to make final determinations after public comment.
Q: What new CPT code was approved for EsoCheck procedures?
A: The code is intended for physician and health-system reporting.
Q: What does proposed ICD-10-CM code R85.83 cover?
A: Proposed code R85.83 would identify positive EsoGuard results involving its targeted methylated DNA biomarkers. It would support claims for subsequent confirmatory upper endoscopy.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.